Annual Secretarial Compliance for the financial year ended March 31, 2025, is enclosed.
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech has submitted its Annual Secretarial Compliance Report for the financial year 2024-25, as required under SEBI's Listing Regulations. The report was prepared by Practicing Company Secretary Sandeep Joshi after reviewing the company's filings, records, and website. The report confirms that the company complied with all applicable SEBI regulations, including the Insider Trading Regulations, LODR Regulations, and Secretarial Standards issued by ICSI. No actions or penalties were imposed by SEBI or stock exchanges during the review period, and no non-compliances were observed. All required policies were adopted and updated on time, related party transactions were approved by the Audit Committee, and no statutory auditor resignations occurred during the year.
This is a routine annual regulatory filing with a clean compliance record, indicating good corporate governance. It carries no negative implications for shareholders and is unlikely to affect the stock price.